Sale!

IDH1 Gene Metaphyseal Chondromatosis with Increased Urinary Excretion of D-2-Hydroxyglutarate NGS Genetic DNA Test

Original price was: $700.Current price is: $500.

-29%

The IDH1 Gene Metaphyseal Chondromatosis with Increased Urinary Excretion of D-2-Hydroxyglutarate NGS Genetic DNA Test is a specialized diagnostic tool that identifies mutations in the IDH1 gene associated with rare bone metabolism disorders. This comprehensive test utilizes Next-Generation Sequencing technology to detect specific genetic abnormalities that cause metaphyseal chondromatosis and abnormal D-2-hydroxyglutarate metabolism. The test provides crucial information for diagnosing rare skeletal conditions, guiding treatment decisions, and understanding inheritance patterns. For patients experiencing unexplained bone abnormalities, skeletal deformities, or metabolic disorders, this test offers definitive answers and personalized medical insights. The test costs $500 USD and delivers results within 3-4 weeks using blood, extracted DNA, or blood spot samples.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

IDH1 Gene Metaphyseal Chondromatosis with Increased Urinary Excretion of D-2-Hydroxyglutarate NGS Genetic DNA Test

Comprehensive Introduction to IDH1 Genetic Testing

The IDH1 Gene Metaphyseal Chondromatosis with Increased Urinary Excretion of D-2-Hydroxyglutarate NGS Genetic DNA Test represents a cutting-edge diagnostic approach for identifying rare genetic bone metabolism disorders. This specialized test focuses on mutations in the IDH1 (Isocitrate Dehydrogenase 1) gene, which plays a critical role in cellular metabolism and bone development. When mutations occur in this gene, they can lead to complex skeletal abnormalities and metabolic disturbances that significantly impact patient health and quality of life.

This advanced genetic analysis is particularly important because IDH1 mutations affect the conversion of isocitrate to alpha-ketoglutarate in the citric acid cycle. Disruptions in this metabolic pathway can result in abnormal accumulation of D-2-hydroxyglutarate, a metabolite that interferes with normal bone development and cellular differentiation processes. The test’s significance extends beyond diagnosis, providing essential information for treatment planning, genetic counseling, and family risk assessment.

What This Advanced Genetic Test Measures and Detects

Our comprehensive NGS-based genetic test specifically targets and analyzes:

  • Mutations in the IDH1 gene associated with metaphyseal chondromatosis
  • Genetic variations causing abnormal D-2-hydroxyglutarate metabolism
  • Specific nucleotide changes affecting enzyme function and bone development
  • Inheritance patterns and familial risk factors
  • Metabolic pathway disruptions impacting skeletal formation

The test utilizes Next-Generation Sequencing technology, which provides unparalleled accuracy in detecting even the most subtle genetic variations. This high-resolution analysis examines the entire coding region of the IDH1 gene, ensuring comprehensive coverage of potential mutation sites that could contribute to the development of metaphyseal chondromatosis and associated metabolic abnormalities.

Who Should Consider This Genetic Test

Clinical Indications and Symptoms

This specialized genetic test is recommended for individuals presenting with:

  • Unexplained skeletal abnormalities in childhood or adulthood
  • Metaphyseal chondromatosis diagnosis or suspicion
  • Elevated urinary D-2-hydroxyglutarate levels
  • Family history of bone metabolism disorders
  • Progressive skeletal deformities affecting long bones
  • Multiple enchondromas or cartilage tumors
  • Developmental delays associated with skeletal abnormalities
  • Unexplained metabolic disorders with skeletal involvement

Specialty Referral Considerations

Patients are typically referred for this testing by:

  • Orthopedic specialists managing skeletal abnormalities
  • Geneticists evaluating inherited bone disorders
  • Metabolic disease specialists investigating D-2-hydroxyglutarate abnormalities
  • Pediatricians observing developmental skeletal issues
  • Oncologists managing cartilage tumor syndromes

Significant Benefits of Genetic Testing

Undergoing the IDH1 genetic test provides numerous clinical advantages:

Accurate Diagnosis and Classification

This test delivers definitive molecular diagnosis, distinguishing IDH1-related metaphyseal chondromatosis from other skeletal dysplasias with similar clinical presentations. Accurate classification enables targeted management strategies and eliminates diagnostic uncertainty.

Personalized Treatment Planning

Genetic results inform evidence-based treatment decisions, including surgical interventions, metabolic management, and surveillance protocols tailored to the specific genetic mutation identified.

Family Risk Assessment

The test provides crucial information for genetic counseling, helping families understand inheritance patterns, recurrence risks, and reproductive options.

Proactive Health Management

Early genetic identification allows for proactive monitoring of potential complications, including malignant transformation risk assessment and preventive care strategies.

Understanding Your Genetic Test Results

Our comprehensive genetic counseling support helps patients interpret their results effectively:

Positive Result Interpretation

A positive result indicates the presence of a pathogenic IDH1 mutation associated with metaphyseal chondromatosis and D-2-hydroxyglutarate metabolism abnormalities. This confirmation enables:

  • Definitive diagnosis establishment
  • Personalized treatment protocol development
  • Family member testing recommendations
  • Long-term surveillance planning

Negative Result Interpretation

A negative result suggests that IDH1 mutations are not responsible for the clinical presentation, guiding physicians toward alternative diagnostic considerations and additional testing if warranted.

Variant of Uncertain Significance

In some cases, genetic variations of uncertain clinical significance may be identified. Our genetic counseling team provides comprehensive guidance on monitoring, additional testing, and family studies to clarify variant implications.

Test Information and Pricing

Test Parameter Details
Test Name IDH1 Gene Metaphyseal Chondromatosis with Increased Urinary Excretion of D-2-Hydroxyglutarate NGS Genetic DNA Test
Regular Price $700 USD
Discount Price $500 USD
Turnaround Time 3 to 4 Weeks
Sample Type Blood, Extracted DNA, or One Drop Blood on FTA Card
Testing Method Next-Generation Sequencing (NGS) Technology
Specialties Genetics, Osteology, Dermatology, Immunology

Pre-Test Preparation Requirements

To ensure optimal testing outcomes, patients should provide:

  • Complete clinical history documentation
  • Genetic counseling session completion
  • Detailed pedigree chart of affected family members
  • Relevant medical imaging and laboratory results
  • Informed consent for genetic testing

Nationwide Testing Availability

We proudly offer comprehensive genetic testing services across the United States, with convenient locations in:

  • New York City and surrounding metropolitan areas
  • Los Angeles and Southern California regions
  • Chicago and Midwest locations
  • Houston and Texas facilities
  • Phoenix and Southwest testing centers
  • All other major metropolitan areas nationwide

Our network of certified genetic testing facilities ensures accessible, reliable, and timely service delivery regardless of your location within the United States.

Take Action Today – Schedule Your Genetic Test

Don’t let uncertainty about skeletal abnormalities and metabolic disorders impact your quality of life. Our specialized IDH1 genetic testing provides the answers you need for informed medical decisions and personalized care planning.

Call or WhatsApp our genetic specialists today at +1(267) 388-9828 to schedule your comprehensive genetic evaluation. Our team is available to discuss your specific concerns, explain the testing process in detail, and help you take the first step toward definitive diagnosis and effective management of your condition.

Take control of your genetic health journey with the advanced diagnostic capabilities of Next-Generation Sequencing technology. Contact us now to book your IDH1 Gene Metaphyseal Chondromatosis with Increased Urinary Excretion of D-2-Hydroxyglutarate NGS Genetic DNA Test and receive the clarity you deserve.